Iovance Biotherapeutics, Inc. SEC filings IOVA
Iovance Biotherapeutics, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Oct 1, 2010. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| CORRESP | Letter to the SEC | Nov 17, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 26, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2023 | — |
| PRER14A | Filing | Apr 19, 2023 | — |
| CT ORDER | Filing | Nov 8, 2019 | — |
| EFFECT | Filing | Sep 24, 2019 | — |
| CORRESP | Letter to the SEC | Sep 20, 2019 | — |
| CORRESP | Letter to the SEC | Sep 17, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2019 | — |
| EFFECT | Filing | Oct 3, 2018 | — |
| CORRESP | Letter to the SEC | Oct 1, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 18, 2018 | — |
| EFFECT | Filing | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Jan 17, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2018 | — |
| CT ORDER | Filing | Sep 28, 2017 | — |
| EFFECT | Filing | Aug 3, 2017 | — |
| EFFECT | Filing | Aug 3, 2017 | — |
| EFFECT | Filing | Aug 3, 2017 | — |
| 8-A12B/A | Filing | Jul 27, 2017 | — |
| CT ORDER | Filing | Apr 6, 2017 | — |
| EFFECT | Filing | Jan 11, 2017 | — |
| CT ORDER | Filing | Dec 23, 2016 | — |
| EFFECT | Filing | Nov 1, 2016 | — |
| CORRESP | Letter to the SEC | Oct 28, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2016 | — |
| EFFECT | Filing | Oct 17, 2016 | — |
| EFFECT | Filing | Oct 17, 2016 | — |
| CT ORDER | Filing | Oct 17, 2016 | — |
| EFFECT | Filing | Sep 2, 2016 | — |
| CORRESP | Letter to the SEC | Sep 1, 2016 | — |
| CORRESP | Letter to the SEC | Aug 12, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 10, 2016 | — |
| EFFECT | Filing | Aug 3, 2016 | — |
| CORRESP | Letter to the SEC | Aug 1, 2016 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2016 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2016 | — |
| CORRESP | Letter to the SEC | Jul 7, 2016 | — |
| PRER14A | Filing | Jul 7, 2016 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2016 | — |
| D | Filing | Jun 15, 2016 | — |
| EFFECT | Filing | May 23, 2016 | — |
| CORRESP | Letter to the SEC | May 20, 2016 | — |
| UPLOAD | Letter from the SEC | May 20, 2016 | — |
| CT ORDER | Filing | Mar 8, 2016 | — |
| EFFECT | Filing | Jul 24, 2015 | — |
| EFFECT | Filing | Jul 8, 2015 | — |
| CORRESP | Letter to the SEC | Jul 6, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2015 | — |
| EFFECT | Filing | Apr 23, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 23, 2015 | — |
| CORRESP | Letter to the SEC | Apr 22, 2015 | — |
| CORRESP | Letter to the SEC | Apr 22, 2015 | — |
| CT ORDER | Filing | Apr 21, 2015 | — |
| CERTNAS | Auto-generated paper document | Feb 25, 2015 | — |
| 8-A12B | Lion biotechnologies form 8-a | Feb 25, 2015 | — |
| EFFECT | Filing | Dec 10, 2014 | — |
| EFFECT | Filing | Sep 29, 2014 | — |
| CT ORDER | Filing | Sep 8, 2014 | — |
| EFFECT | Filing | Apr 16, 2014 | — |
| EFFECT | Filing | Jan 30, 2014 | — |
| CORRESP | Letter to the SEC | Jan 28, 2014 | — |
| CORRESP | Letter to the SEC | Jan 21, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2014 | — |
| CORRESP | Letter to the SEC | Jan 7, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2013 | — |
| D | Filing | Nov 15, 2013 | — |
| SC 14F1 | Schedule 14f-1 | Aug 22, 2013 | — |
| NT 10-Q | Genesis biopharma notification of late filing | Aug 15, 2013 | Jun 30, 2013 |
| D | Filing | Jun 6, 2013 | — |
| NT 10-K | Genesis biopharma notification of late filing | Apr 1, 2013 | Dec 31, 2012 |
| NT 10-Q | Notification of late filing | Nov 13, 2012 | Sep 30, 2012 |
| NT 10-Q | Notification of late filing | Aug 10, 2012 | Jun 30, 2012 |
| NT 10-Q | Notification of late filing | May 11, 2012 | Mar 31, 2012 |
| NT 10-K | Filing | Mar 15, 2012 | Dec 31, 2011 |
| UPLOAD | Letter from the SEC | Dec 20, 2011 | — |
| CT ORDER | Filing | Dec 19, 2011 | — |
| EFFECT | Filing | Dec 16, 2011 | — |
| CORRESP | Letter to the SEC | Dec 14, 2011 | — |
| CORRESP | Letter to the SEC | Dec 5, 2011 | — |
| NT 10-Q | Filing | Nov 15, 2011 | Sep 30, 2011 |
| UPLOAD | Letter from the SEC | Nov 10, 2011 | — |
| CORRESP | Letter to the SEC | Oct 27, 2011 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2011 | — |
| NT 10-Q | Notification of late filing for form 10q | Aug 16, 2011 | Jun 30, 2011 |
| CORRESP | Letter to the SEC | Aug 10, 2011 | — |
| D | Filing | Aug 9, 2011 | — |
| NT 10-Q | Filing | May 16, 2011 | Mar 31, 2011 |
| D | Filing | May 3, 2011 | — |
| NT 10-K | Filing | Apr 1, 2011 | Dec 31, 2010 |
| D | Filing | Jan 21, 2011 | — |
| NT 10-Q | Filing | Nov 16, 2010 | Sep 30, 2010 |
| D | Filing | Nov 8, 2010 | — |
| D | Filing | Oct 1, 2010 | — |
Showing 95 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IOVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1425205
- Former names
- Lion Biotechnologies, Inc. (until Jun 5, 2017); Genesis Biopharma, Inc (until Sep 23, 2013); FREIGHT MANAGEMENT CORP (until Mar 8, 2010)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.